Apolipoprotein E polymorphisms and risk of hypercholesterolemia: A case-control study in a working population from Valencia, Spain;Polimorfismos en el gen de la apolipoproteína E y riesgo de hipercolesterolemia: Un estudio de casos y controles en una población laboral de Valencia

Medicina Clinica

Volumn 115, Issue 5, 2000, Pages 170-175

  Corella, Dolores ^a   Guillén, Marisa ^a   Portolés, Olga ^a   Sabater, Antonio ^a   Cortina, Silvia ^a   Folch, José ^a   Sáiz, Carmen ^a  

^a NONE

Author keywords

Apolipoprotein E; Gene APOE; Hypercholesterolemia; Polymorphisms

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELE; ARTICLE; COMPARATIVE STUDY; DRINKING BEHAVIOR; EDUCATION; EXERCISE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RANDOMIZATION; RISK; RISK FACTOR; SMOKING; SPAIN; STATISTICAL ANALYSIS;

ADULT; ALCOHOL DRINKING; ALLELES; APOLIPOPROTEINS E; DATA INTERPRETATION, STATISTICAL; EDUCATION; EXERCISE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; LIFE STYLE; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RANDOM ALLOCATION; RISK FACTORS; SMOKING; SPAIN;

EID: 0034220953     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71498-9     Document Type: Article

References (56)

1. Barter PJ. Cholesterol and cardiovascular disease: basic science. Aust N Z J Med 1994; 24: 83-88.
2. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framigham Heart Study. N Engl J Med 1990; 322: 1635-1641.
3. Bodurtha JN, Chen CW, Mosteller M, Nance WE, Schieken RM, Segrest J. Genetic and environmental contributions to cholesterol and its subfractions in 11-year-old twins: The Medical College of Virginia twin study. Arterioscler Thromb 1991; 11: 844-850.
4. Hegele RA. Gene-environment interactions in atherosclerosis. Mol Cell Biochem 1991; 113: 177-186.
5. Bijnen FCH, Feskens EJM, Caspersen CJ, Giampaoli S, Nissinen AM, Menotti A et al. Physical activity and cardiovascular risk factors among elderly men in Finland, Italy, and the Netherlands. Am J Epidemiol 1996; 143: 553-561.
6. Fujishima M, Kiyohara Y, Ueda K, Hasuo Y, Kato I, Iwamoto H. Smoking as cardiovascular risk factor in low cholesterol population: the Hisayama Study. Clin Exp Hypertens 1992; 14A: 99-108.
7. Ellsworth DL, Sholinsky P, Jaquish C, Fabsitz RR, Manolio TA. Coronary heart disease. At the interface of molecular genetics and preventive medicine. Am J Prev Med 1999; 16: 122-133.
8. Talmud P, Tybjærg-Hansen A, Bhatnagar D, Mbewu A, Miller JP, Durrington P et al. Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis 1991; 89: 137-141.
9. Bétard C, Kessling AM, Roy M, Davignon J. Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a "null" LDL-receptor gene defect. Atherosclerosis 1996; 119: 43-55.
10. Connelly PW, Maguire GF, Lee M, Little JA. Plasma lipoproteins in familial hepatic lipase deficiency. Arterioscler Thromb 1990; 10: 40-48.
11. Reina M, Brunzell JD, Deeb SS. Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes. J Lipid Res 1992; 33: 1823-1832.
12. Kamboh MI, Evans RW, Aston CE. Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women. Atherosclerosis 1995; 117: 73-81.
13. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arterioscler Thromb 1988; 8: 1-21.
14. Hixson JE, PDAY Research Group. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb 1991; 11: 1237-1244.
15. Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 1995; 112: 145-159.
16. Myers RH, Schaefer EJ, Wilson PWF, D'Agostino R, Ordovas JM, Espino A et al. Apolipoprotein E ε4 association with dementia in a population-based study: The Framingham study. Neurology 1996; 46: 673-677.
17. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671.
18. Lahoz C, Ordovés JM. ApoE: lipidos plasméticos, cardiopatía isquémica y enfermedad de Alzheimer. Med Clin (Barc) 1997; 109: 31-36.
19. Breslow JL, McPherson J, Nussbaum AL, Williams HW, Lofquist-Kahl F, Karathanasis SK. Identification and DNA sequence of a human apolipoprotein E cDNA clone. J Biol Chem 1982; 257: 14639-14641.
20. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 1984; 25: 310-313.
21. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37: 268-285.
22. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987; 113: 433-440.
23. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. Clin Chim Acta 1999; 286: 115-143.
24. Tiret L, De Knijff P, Wenzel H-J, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: The EARS Study. Arterioscler Thromb 1994; 14: 1617-1624.
25. Aguilar CA, Talavera G, Ordovás JM, Barriguete JA, Guillen LE. Leco ME et al. The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a Native American population following its traditional lifestyle. Atherosclerosis 1999; 142: 409-414.
26. Deiana L, Pes GM, Carru C, Errigo A, Pettinato S, Carcassi C et al. Lack of influence of apolipoprotein E4 on lipoprotein levels in the island population of Sardinia. Eur J Clin Invest 1998; 28: 290-294.
27. Pérez-Estrada E, Escolar JL, Valdivielso P, Andrade R, Pérez-Estrada M, González-Santos P. Fenotipos de la apoproteina E. Un estudio de la población de Málaga. Rev Clin Esp 1990; 187: 3-5.
28. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Jürgen Menzel H, Csázár A et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991; 49: 338-349.
29. Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the World. Genet Epidemiol 1992; 9: 155-167.
30. Lucotte G, Loirat F, Hazout S. Pattern of gradient of apolipoprotein. E allele ε4 frequencies in western Europe. Hum Biol 1997; 69: 253-262.
31. Muros M, Rodríguez-Ferrer C. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4. Atherosclerosis 1996; 121: 13-21.
32. Gómez-Coronado D, Alvarez JJ, Entrala A, Olmos JM, Herrera E, Lasuncion MA, Apolipoprotein E in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins. Atherosclerosis 1999; 147: 167-175.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparatie ultracentrifuge. Clin Chem 1972; 18: 499-502.
34. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990; 31: 545-548.
35. Corella D, Sáiz C, Guillén M, Portolés O, Mulet F, Gonzalez JI et al. Association of TaqlB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis 2000. En prensa.
36. Cariolou MA, Kokkofitou A, Manoli P, Christou S, Karagrigoriou A, Middleton L. Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Genet Epidemiol 1995; 12: 489-497.
37. Lehtimäki T, Moilanen T, Nikkari T, Solakivi T, Porkka K, Ehnholm C et al. Regional differences in apolipoprotein E polymorphism in Finland. Ann Med 1991; 23: 61-66.
38. Gené M, Moreno P, Esquerra M, Prat A. Huguet E, Adroer R et al. Low apoliprotein E E4 allele frequency in the population of Catalonia (Spain) determined by PCR-RFLP and laser fluorescent sequencer. Eur J Epidemiol 1997; 13: 841-843.
39. The Expert Panel. Summary of the second report of the National Cholesterol Education Program (CNEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015-3023.
40. Sociedad Espanola de Arteriosclerosis, Sociedad Española de Medicina Interna, y Liga Lucha contra la Hipertensión Arterial. Recomendaciones para la prevención primaria de la enfermedad cardiovascular. Clin Invest Arterioscler 1994; 6: 62-102.
41. Martin MJ, Hulley SB, Browner WS, Kuller LH, Ventworth D, Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; 2: 933-936.
42. Gómez-Gerique JA, Gutiérrez-Fuentes JA, Montoya MT. Porres A, Rueda A, Avelaneda A et al. Perfil lipídico de la población española: estudio DRECE (Dieta y Riesgo de Enfermedad Cardiovascular en España). Med Clin (Barc) 1999; 113: 730-735.
43. Chaves FJ, Puig O, García-Sogo M, Real J, GI JV, Ascaso JF et al. Seven DNA polymophisms in the LDL receptor gene: application to the study of familial hypercholesterolemia in Spain, Clin Genet 1996; 50: 28-35.
44. Jrvik GP, Beaty TH, Gallagher PR, Coates PM, Cortner JA. Genotype at a major locus with large effects on apolipoprotein B levels predicts familial combined hyperlipidemia. Genet Epidemiol 1993; 10: 257-270.
45. Alonso-Villaverde C, Sardà P,l Vallve JC, Heras M, Pérez-Jimenez F, Pedro-Botet JC et al. Manifestaciones clínicas de la hipercolesterolemia familiar en una población mediterránea. Med Clin (Barc) 1999; 113: 521-525.
46. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovás JM, Schaefer MM, Castelli WP et al. Effects of gender and menopausa status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: Results from tne Framingham Offspring Study. Arterioscler Thromb 1994; 14: 1105-1113.
47. Wilson PWF, Schaefer EJ, Larson MG, Ordovás JM. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vase Biol 1996; 16: 1250-1255.
48. Howard BV, Gidding SS, Liu K. Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. Am J Epidemiol 1998; 148: 859-868.
49. Khoury MJ, Yang Q. From genes to public health: the application of genetic technology in disease prevention. Am J Public Health 1996; 86: 1717-1722.
50. Coughlin SS. The intersection of genetics, public health, and preventive medicine. Am J Prev Med 1999; 16: 89-90.
51. Ordovas JM, Schaefer EJ. Genes, variation of cholesterol and fat intake and serum lipids. Curr Opin Lipidol 1999; 10: 15-22.
52. Ordovas JM. The genetics of serum lipid responsiveness to dietary interventions. Proc Nutr Soc 1999; 58: 171-187.
53. Ordovas JM, López-Miranda J, Pérez-Jiménez F, Rodriguez CR, Park J-S, Cole T et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy. Atherosclerosis 1995; 113: 157-166.
54. Ordovas JM, Schaefer EJ. Treatment of dyslipidemia: genetic interactions with diet and drug therapy, Curr Atheroscler Rep 1999; 1: 16-23.
55. Boer JMA, Ehnholm C, Menzel H-J, Havekes L, Roseneu M, O'Reilly DS et al. Interaction between lifestyle-related factors and the apoE polymorphism or plasma lipids and apolipoproteins. The EARS study. Arterioscler Thromb Vasc Biol 1997; 17: 1675-1681.
56. Hagberg JM, Ferrel RE, Dengel DR, Wilund KR. Exercise training-induced blood pressure and plasma lipid improvements in hypertensives may be genotype dependent. Hypertension 1999; 34: 18-23.